Daratumumab
- Generic Name
- Daratumumab
- Brand Names
- Darzalex, Darzalex Faspro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 945721-28-8
- Unique Ingredient Identifier
- 4Z63YK6E0E
- Background
Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind.
...
- Indication
Daratumumab is indicated as an intravenous injection alone or in combination with other medications for the treatment of multiple myeloma. It is available as a combination product with hyaluronidase for the treatment of adults with multiple myeloma as monotherapy or combination therapy and light chain amyloidosis in combination with other drugs.
- Associated Conditions
- Multiple Myeloma (MM), Primary Amyloidosis, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM
- Conditions
- Interventions
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2021-10-21
- Target Recruit Count
- 76
- Registration Number
- NCT05088330
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 587
- Registration Number
- NCT05083169
- Locations
- 🇺🇸
Emory University - Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸West Penn Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 29
- Registration Number
- NCT05054478
MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 761
- Registration Number
- NCT05020236
- Locations
- 🇺🇸
MSK Bergen, Montvale, New Jersey, United States
🇺🇸MSK Commack, Commack, New York, United States
🇺🇸MSK Westchester, Harrison, New York, United States
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 864
- Registration Number
- NCT04975997
- Locations
- 🇺🇸
Ohio Health Corporation, Columbus, Ohio, United States
🇺🇸MetroHealth Medical Center - Main Campus, Cleveland, Ohio, United States
🇺🇸Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio, United States
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 30
- Registration Number
- NCT04972942
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-06-21
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 11
- Registration Number
- NCT04933539
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 18
- Registration Number
- NCT04925193
- Locations
- 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- West Virginia University
- Target Recruit Count
- 16
- Registration Number
- NCT04922723
- Locations
- 🇺🇸
West Virginia University Cancer Institute Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States
Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.
- Conditions
- Interventions
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 28
- Registration Number
- NCT04915248
- Locations
- 🇮🇹
A.O. Universitaria Ospedali Riuniti - Ospedale Umberto I Di Ancona, Ancona, Italy
🇮🇹Aviano - IRCCS Centro di Riferimento Oncologico di Aviano - Divisione di Oncologia e dei Tumori immuto-correlati, Aviano, Italy
🇮🇹A.O. Spedali Civili di Brescia - Ematologia, Brescia, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.